Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
XACT Robotics has secured a CE mark for its XACT image-guided robotic needle steering system for CT-guided percutaneous procedures in the abdomen. The company is hoping to formally launch XACT by 2019 while expanding the system to additional clinical indications, including spine, and lung procedures.
Latest From Companies
Medtronic is straightening up as a market leader in spinal surgery after agreeing to buy the shares of Mazor Robotics that it does not already own. The $1.3bn deal builds on an existing agreement between the companies formed in May 2016 and strengthens Medtronic as the front runner in the spine robotics field.
An anterior cruciate ligament (ACL) repair technology developed by MIACH Orthopedics has secured backing from investors, including the union for National Football League players, in a new round of financing. See what MIACH founder Martha Murray said about it here.
MIACH Orthopedics, has secured $22.5m from investors including the NFL Players Association to continue US clinical trials for its Bridge-Enhanced ACL Repair (BEAR) technology.
Just weeks after inking a billion-dollar acquisition of K2M, Stryker has announced a $190m deal to acquire photonics firm Invuity. Under the terms of the agreement, a subsidiary of Stryker will purchase all outstanding shares of Invuity for $7.40 per share in cash.
A new guidance from the UK's National Institute for Health and Care Excellence (NICE) concludes that sutureless aortic valve replacement is an alternative to conventional surgical aortic valve replacement. The NICE guidance came as LivaNova announced completed enrollment in the 900-patient, randomized PERSIST-AVR trial of its Perceval sutureless aortic valv.
Inivata's Chief Medical Officer Clive Morris will take over as CEO of the liquid biopsy company. Former CEO Michael Stocum departed earlier this year.
Creavo Medical Technologies is trying to make "magnetocardiography" a go-to tool for emergency departments in diagnosing heart disease. See what Creavo CEO Steve Parker had to say about evidence backing the technology.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.